Competitive Technologies, Inc.

  • ISIN: US2045121074
  • Land: .

Nachricht vom 21.09.2011 | 19:38

Competitive Technologies Announces New International Distributors for Calmare(R) Scrambler Therapy(TM) Medical Devices


Competitive Technologies, Inc. 

21.09.2011 19:38
---------------------------------------------------------------------------

FAIRFIELD, Conn., 2011-09-21 19:38 CEST (GLOBE NEWSWIRE) --
Competitive Technologies, Inc. (OTCQX:CTTC) today announced that it has signed
two new international distribution agreements that have resulted in immediate
orders for Calmare(r) Scrambler Therapy(tm) medical devices. The new distributors
are Ahsan Anaesthetist Ltd., which will be responsible for sales in Ireland,
and the Mediterranean for Technology & Trading SAL Offshore (MTT- Elyssa
Holding), which will be responsible for sales in sixteen countries in the
Middle East and North Africa. 

'We are pleased to see the increased utilization of the Calmare Scrambler
Therapy device internationally,' said Umberto Marangoni, CTTC's Managing
Director of International Business Development. 'We believe these agreements
and a number of others we are currently negotiating in additional countries are
a reflection of the increased worldwide interest in our non-invasive pain
therapy which is free of harmful side effects.' 

About Competitive Technologies, Inc

Competitive Technologies is a global leader in developing and commercializing
innovative products and technologies. CTTC is multifaceted, providing
distribution, patent and technology transfer, sales and licensing services.
CTTC's staff is focused on the needs of customers and matching those
requirements with commercially viable products or technology solutions. 

CTTC is the licensed worldwide distributor of the non-invasive Calmare(r) pain
therapy medical device, which incorporates the biophysical 'Scrambler Therapy(tm)'
technology developed in Italy by CTTC's client, Professor Giuseppe Marineo to
treat neuropathic pain, including cancer pain. The Calmare(r) device is currently
being manufactured for sale by CTTC's partner, GEOMC Co., Ltd. of Seoul, Korea.
For more information on the device, visit www.calmarett.com. Visit CTTC's
website: www.competitivetech.net. 

Statements made about our future expectations are forward-looking statements
and subject to risks and uncertainties as described in our most recent Annual
Report on Form 10-K for the year ended July 31, 2010, filed with the SEC on
October 27, 2010, and other filings with the SEC, and are subject to change at
any time. Our actual results could differ materially from these forward-looking
statements. We undertake no obligation to update publicly any forward-looking
statement. 


         CONTACT:  Jean Wilczynski
         IR Services, LLC
         (860.434.2465
         info@corpirservices.com)
News Source: NASDAQ OMX



21.09.2011 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Competitive Technologies, Inc.
              
               
              United States
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         US2045121074
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------

Anleihe im Fokus

8,25% Maritim-Offshore-Anleihe

Die besicherte Maritim-Offshore-Anleihe (WKN A1MLY9 / ISIN DE000A1MLY97) mit einem Volumen von bis zu € 25 Mio. und einem Zinssatz von 8,25% kann ab dem 21. Mai 2012 gezeichnet werden.
Die Laufzeit der Anleihe beträgt 2,5 Jahre, der Kupon wird halbjährlich bezahlt.

Event im Fokus

13. MKK

13. MKK - Münchner Kapitalmarkt Konferenz
am 23. & 24. Mai 2012
Über 20 Gesellschaften aus dem Small- und Mid-Cap Bereich präsentieren sich
im SOFITEL Munich Bayerpost

GBC-Fokusbox

HELMA Eigenheimbau: Rekordwerte

Im abgelaufenen Geschäftsjahr legte HELMA Eigenheimbau AG bei der Umsatz– und Ergebnisdynamik deutlich zu und erreichte damit neue Rekordwerte. Auf Basis unseres DCF-Modells haben wir einen 2012er fairen Unternehmenswert von 19 € je Aktie ermittelt. Unser Rating lautet „KAUFEN“.

News im Fokus

SAP AG: SAP erweitert Cloud-Geschäft mit Akquisition von Ariba

22. Mai 2012, 20:48

Aktuelle Research-Studie

MPH Mittelständische Pharma Holding AG

Original-Research: MPH Mittelständische Pharma Holding AG (von GBC AG): KAUFEN

22. Mai 2012